Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Sodium benzoate-induced angioedema-urticaria (disorder) |
Causative agent (attribute) |
True |
Sodium benzoate |
Inferred relationship |
Some |
2 |
Caffeine and sodium benzoate injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sodium benzoate |
Inferred relationship |
Some |
|
Product containing sodium benzoate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sodium benzoate |
Inferred relationship |
Some |
1 |
Product containing caffeine and sodium benzoate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sodium benzoate |
Inferred relationship |
Some |
1 |
Product containing sodium benzoate and sodium phenylacetate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sodium benzoate |
Inferred relationship |
Some |
2 |
Sodium benzoate 100 mg/mL and sodium phenylacetate 100 mg/mL solution for injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sodium benzoate |
Inferred relationship |
Some |
|
Caffeine- and sodium benzoate-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sodium benzoate |
Inferred relationship |
Some |
1 |
Caffeine and sodium benzoate only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sodium benzoate |
Inferred relationship |
Some |
1 |
Product containing only sodium benzoate and sodium phenylacetate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sodium benzoate |
Inferred relationship |
Some |
2 |
Product containing only sodium benzoate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sodium benzoate |
Inferred relationship |
Some |
1 |
Product containing only caffeine and sodium benzoate in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sodium benzoate |
Inferred relationship |
Some |
1 |
Sodium benzoate- and sodium phenylacetate-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sodium benzoate |
Inferred relationship |
Some |
2 |
Product containing only sodium benzoate and sodium phenylacetate in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sodium benzoate |
Inferred relationship |
Some |
2 |
Sodium benzoate 100 mg/mL and sodium phenylacetate 100 mg/mL solution for injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sodium benzoate |
Inferred relationship |
Some |
2 |
Sodium benzoate 100 mg/mL and sodium phenylacetate 100 mg/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sodium benzoate |
Inferred relationship |
Some |
2 |
Sodium benzoate-induced angioedema-urticaria (disorder) |
Causative agent (attribute) |
True |
Sodium benzoate |
Inferred relationship |
Some |
1 |